Physician profile
Dennis E Sumski
NPI 1235180423
$881.71
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $39.90 · 2021: $89.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $185.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $131.95 | 2019 | |
| Abbvie INC. | $89.78 | 2021 | |
| Daiichi Sankyo INC. | $82.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.39 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $47.59 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.29 | 2019 | |
| Glaxosmithkline, LLC. | $36.00 | 2019 | |
| Lilly USA, LLC | $28.49 | 2019-2020 | |
| Medtronic USA, INC. | $27.26 | 2019 | |
| Amarin Pharma, INC. | $26.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.56 | 2019 | |
| Pfizer INC. | $15.59 | 2019 | |
| Sanofi Pasteur INC. | $15.50 | 2019 | |
| Boston Scientific Corporation | $14.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.83 | 2019 | |
| Amgen INC. | $11.71 | 2019 | |
| Shire North American Group INC | $11.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Sumski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.